A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase III Study to Evaluate Corticosteroid-reduction and -sparing Effects of Mepolizumab 750 mg Intravenous in Subjects with Hypereosinophilic Syndromes (HES), and to Evaluate the Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of HES over Nine Months.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000929-30-IT

Enrollment

Registered

2005-05-12

Start date

2004-07-08

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HES MedDRA version: 6.1 Level: PT Classification code 10048643

Interventions

Product Name: Mepolizumab Product Code: SB240563 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: SB-240563 Concentration unit: mg milligram(s) Concentration type: equa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026